Acute lymphoblastic leukemia: a comprehensive review and 2017 update

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

(2016) Michael E. Rytting et al.   AMERICAN JOURNAL OF HEMATOLOGY

XLF deficiency results in reduced N-nucleotide addition during V(D)J recombination

(2016) H. IJspeert et al.   BLOOD

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2016) N. J. Short et al.   BLOOD

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

(2016) N. Jain et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis

(2016) Koji Sasaki et al.   CANCER

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples

(2016) Benjamin Y. Lu et al.   LEUKEMIA & LYMPHOMA

Adult Acute Lymphoblastic Leukemia

(2016) Shilpa Paul et al.   MAYO CLINIC PROCEEDINGS

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine

(2015) S. P. Hunger et al.   BLOOD

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

(2015) J. J. M. van Dongen et al.   BLOOD

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

(2015) N. Dhedin et al.   BLOOD

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

(2015) Aradhana Awasthi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2015) Farhad Ravandi et al.   CANCER

New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

(2015) Elias Jabbour et al.   CANCER

Acute Lymphoblastic Leukemia, Version 2.2015

(2015) Joseph C. Alvarnas et al.   Journal of the National Comprehensive Cancer Network

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Characterization of CD22 expression in acute lymphoblastic leukemia

(2015) Nirali N. Shah et al.   PEDIATRIC BLOOD & CANCER

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

(2015) Eric J. Smith et al.   Scientific Reports

DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia

(2015) Jessica Nordlund et al.   Clinical Epigenetics

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

(2015) Kathryn G. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels

(2015) Daniela Bressanin et al.   Oncotarget

A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia

(2014) Michael J. Burke et al.   AMERICAN JOURNAL OF HEMATOLOGY

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Safety and clinical activity of 5-aza-2′-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia

(2014) Christopher B. Benton et al.   BRITISH JOURNAL OF HAEMATOLOGY

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

(2014) Anjali S. Advani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Epigenetic deregulation in pediatric acute lymphoblastic leukemia

(2014) Zac Chatterton et al.   Epigenetics

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

(2014) Josep-Maria Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function

(2013) V. Coelho et al.   BLOOD

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

(2013) F. Ravandi et al.   BLOOD

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

The Anti-CD19 Antibody-Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia

(2013) H. Carol et al.   CLINICAL CANCER RESEARCH

Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia

(2013) David M. Barrett et al.   HUMAN GENE THERAPY

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

(2013) S. Herter et al.   MOLECULAR CANCER THERAPEUTICS

The genomic landscape of hypodiploid acute lymphoblastic leukemia

(2013) Linda Holmfeldt et al.   NATURE GENETICS

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Lymphoblastic Leukemia in Early Childhood as the Presenting Sign of Ataxia-Telangiectasia Variant

(2013) Bella Bielorai et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

(2012) Y. H. Messinger et al.   BLOOD

Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia

(2012) S. K. Tasian et al.   BLOOD

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

(2012) N. Gokbuget et al.   BLOOD

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

(2012) S. L. Maude et al.   BLOOD

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

(2012) Kathryn G. Roberts et al.   CANCER CELL

Augmented Hyper-CVAD Based on Dose-Intensified Vincristine, Dexamethasone, and Asparaginase in Adult Acute Lymphoblastic Leukemia Salvage Therapy

(2012) Stefan Faderl et al.   Clinical Lymphoma Myeloma & Leukemia

Genetic modification of lymphocytes by retrovirus-based vectors

(2012) Julia D Suerth et al.   CURRENT OPINION IN IMMUNOLOGY

CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis

(2012) Elaine Y. Chung et al.   JOURNAL OF CLINICAL INVESTIGATION

High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

(2012) Susan O'Brien et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

DNA Methylation Analysis of Bone Marrow Cells at Diagnosis of Acute Lymphoblastic Leukemia and at Remission

(2012) Jessica Nordlund et al.   PLoS One

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

(2011) W. G. Wierda et al.   BLOOD

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

(2011) R. Foa et al.   BLOOD

A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia

(2011) John Schindler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

(2011) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

Treatment of acute lymphoblastic leukemia in adults

(2011) Sujata Narayanan et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies

(2011) R. M. Sharkey et al.   MOLECULAR CANCER THERAPEUTICS

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

(2010) A. S. Wayne et al.   CLINICAL CANCER RESEARCH

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia

(2010) P. Saunders et al.   HAEMATOLOGICA

High incidence ofEpstein Barr virusinfection in childhood acute lymphocytic lukemia: A preliminary study

(2010) S Sehgal et al.   Indian Journal of Pathology and Microbiology

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

(2010) Deborah A. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

(2010) Pier Paolo Piccaluga et al.   LEUKEMIA & LYMPHOMA

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993

(2009) Adele K. Fielding et al.   BLOOD

DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia

(2009) L. Milani et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia

(2009) Rosemary Sutton et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia

(2009) F. Chiarini et al.   CANCER RESEARCH

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

(2009) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia

(2009) Larry Herrera et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Successful induction therapy with decitabine in refractory childhood acute lymphoblastic leukemia

(2009) L Yánez et al.   LEUKEMIA

Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways

(2009) W-L Zhao   LEUKEMIA

Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia

(2009) Charles G Mullighan et al.   NATURE GENETICS

Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen

(2008) G. G. Laport et al.   BLOOD

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

(2008) K. Porkka et al.   BLOOD

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

(2008) W. Stock et al.   BLOOD

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

(2008) Dan Jones et al.   CANCER

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

(2008) Susan O'Brien et al.   CANCER

Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

(2008) Elizabeth A. Raetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease in Acute Lymphoblastic Leukemia

(2008) Dario Campana   SEMINARS IN HEMATOLOGY